MBRX — Moleculin Biotech Balance Sheet
0.000.00%
- $25.24m
- $17.69m
Annual balance sheet for Moleculin Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 15.2 | 70.9 | 43.1 | 23.6 | 4.28 |
| Net Total Receivables | 0.164 | 0.496 | 1.05 | 1.52 | 0.015 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.2 | 72.5 | 45.6 | 26.3 | 5.19 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.685 | 0.445 | 0.678 | 0.796 | 0.583 |
| Net Intangible Assets | |||||
| Total Assets | 29 | 84.1 | 57.4 | 38.2 | 16.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.92 | 3.62 | 4.82 | 6.82 | 5.36 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.3 | 5.1 | 5.23 | 12.1 | 10.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 17.8 | 79 | 52.2 | 26.1 | 5.98 |
| Total Liabilities & Shareholders' Equity | 29 | 84.1 | 57.4 | 38.2 | 16.9 |
| Total Common Shares Outstanding |